Side effects of<unk>  include somnolence or fatigue (combined preferred terms of "somnolence", "lethargy", "fatigue", "sluggishness"; 6.9–9.6% vs. 1.3% for placebo), headache (4.5–5.9% vs. 3.4% for placebo), and nightmares or abnormal dreams (0.9–2.2% vs. 0.9% for placebo). No residual effects have been found after administration of 25mg<unk>  in the evening to either young or elderly individuals. However,<unk>  may cause next-morning driving impairment at the start of treatment or in some individuals. Orexin receptor antagonists like<unk>  may have less or no propensity for causing tolerance compared to other sedatives and hypnotics based on animal studies.<unk>  did not produce signs of withdrawal or dependence upon discontinuation in animal studies and clinical trials, and orexin receptor antagonists are not associated with rebound insomnia. Loss of sleep-promoting effectiveness occurs rapidly upon discontinuation of<unk> . Preclinical research has suggested that orexin antagonists may reduce appetite, but<unk>  and other orexin antagonists have not been associated with weight loss in rigorous clinical trials. Orexin receptor antagonists can affect the reward system and produce drug-liking responses in humans.<unk>  at a dose of 50mg (the maximum recommended dose) showed significantly greater drug liking than placebo but significantly less drug liking than zolpidem (30mg) and suvorexant (150mg) in recreational sedative drug users. At higher doses of 100 and 150mg (greater than the recommended maximum dose), drug liking with<unk>  was similar to that with zolpidem (30mg) and suvorexant (150mg). In other studies, suvorexant showed similar drug liking compared to zolpidem but lower misuse potential on other measures (e.g., overall rate of misuse potential adverse events of 58% for zolpidem and 31% for suvorexant in recreational drug users). No reports indicative of misuse liability were observed in large clinical trials with<unk> , although these studies excluded participants with history of drug or alcohol misuse.
Daridorexant
Seltorexant
Suvorexant
Veristrat
Bocasan
Toremifene
Icatibant
Fenproporex